Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
348 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Early Access
Lymphoma
B cell lymphoma
Large B cell lymphoma
2
3 or more
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
1
Targeted therapy
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Lymphoma
B cell lymphoma
Large B cell lymphoma
1
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Phase 3
Prostate cancer
#NCT06551324
#2024-511650-50-00
Adenocarcinoma
Metastatic Castration-resistant
Hormone therapy
Targeted therapy
Internal Vectorised Radiotherapy (IVR)
Chemotherapy
Targeted therapy
Internal Vectorised Radiotherapy (IVR)
13 recruiting sites
Pfizer
Phase 3
Lung cancer
#NCT06890598
#2024-512302-25-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
KRAS G12C
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Chemotherapy
Radiotherapy
ALK
EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT06890598
#2024-512302-25-00
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
KRAS G12C
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Surgery
Immunotherapy
Chemotherapy
ALK
EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT06801834
#2024-515884-69-00
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
1
Chemotherapy
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences